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With gastroenteritis as the second leading cause of 
morbidity and mortality worldwide (Guerrant et al. 2001), 
it is imperative to have a laboratory method which is 
highly rapid, sensitive, and cost-effective to aid in the 
diagnosis and treatment of affected patients. This 
validation study seeks to evaluate the Nanosphere
Verigene real-time PCR and microarray assay as a 
potential replacement for the current culture-based 
methods of testing stool samples for enteric pathogens 
in the Bridgeport Hospital microbiology lab.
• To perform a validation of the sensitivity of the Verigene assay in 
comparison to current culture methods for enteric pathogens in stool 
samples.
• To perform a correlation study between the two sample processor 
modules of the instrument to ensure assay accuracy.
• To perform a CAP-required 20 day validation of the internal controls for 
the Verigene assay against commercially-prepared external controls
• To prepare a cost analysis for insurance reimbursement of the Verigene
assay versus culture based methods for detecting enteric pathogens in 
stool samples.
Introduction Objectives
Molecular Diagnostics versus Culture
• Higher sensitivity to detect pathogens at 
lower concentrations
• Reportable results obtained within 2.5 
hours of receiving specimen.
• Tests for multiple pathogen targets 
simultaneously.
• Some species unable to be detected 
due to being fastidious and unculturable.
• Results typically take 48-72 hours to 
obtain.
• Multiple successive tests necessary to 
identify pathogen.
Figure 2. Verigene microarray design for detection of multiple enteric pathogens from a 
single stool sample (Nanosphere, 2014). 
Verigene Enteric 
Pathogens Target
Percent Agreement, 95% CI
Positive Negative
Campylobacter group 97.0 99.0
Salmonella spp. 97.3 99.5
Shigella spp. 98.4 99.0
Vibrio group 91.5 99.9
Yersinia enterocolitica 100 100
Shiga toxin 1 100 99.6
Shiga toxin 2 97.3 99.8
Norovirus G1 and G2 94.8 99.7
Rotavirus A 96.3 99.9
Figure 1. Comparison of Verigene EP assay to culture and enzyme immunoassay 
reference methods. Adapted from the Nanosphere Verigene EP Performance Overview 
(2014).
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Figure 3. Verigene Processor SP drawer assembly. Pictured 
from top to bottom is the test cartridge, amplification tray, tip 
holder assembly, and extraction tray.
Figure 4. The Nanosphere Verigene test cartridge (top) 
contains the substrate holder (bottom left) and reagent 
pack (bottom right). After completion of the automated 
extraction, amplification, and hybridization procedure, the 
substrate holder is separated from the reagent pack and 
interpreted on the Verigene reader.
